2021 年第三季度报告 证券代码：603990 证券简称：麦迪科技 苏州麦迪斯顿医疗科技股份有限公司 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比 | | 年初至报告 | | --- | --- | --- | --- | --- | | | | 上年同期增 | 年初至报告期末 | 期末比上年 | | | | 减变动幅度 | | 同期增减变 | | | | (%) | | 动幅度(%) | | 营业收入 | 66,681,426.07 | -17.24 | 218,113,166.23 | 28.57 | | 归属于上市公司股东的净利润 | -2,195,765.61 | -123.17 | 14,236,656.84 | 705.40 | | 归属于上市公司股东的扣除非 | -5,384,777.60 | -159.88 | 8,995, ...

Financial Performance - The company reported a total revenue of 100 million RMB for the first half of 2021, representing a 20% increase compared to the same period last year[19]. - The net profit for the first half of 2021 was 15 million RMB, which is a 10% increase year-over-year[19]. - The company's operating revenue for the first half of 2021 was ¥151,431,740.16, representing a 70.01% increase compared to the same period last year[21]. - Net profit attributable to shareholders was ¥16,432,422.45, a significant increase from a net loss of ¥7,708,706.95 in the previous year[21]. - The net cash flow from operating activities increased by 46.51% to ¥5,538,355.44, primarily due to the rise in operating revenue[22]. - Basic earnings per share improved to ¥0.10 from a loss of ¥0.07 in the same period last year[22]. - The total profit reached 21.95 million yuan, marking a turnaround from loss to profit compared to the previous year[42]. - The company reported a net loss of ¥10,766,328.17 during the reporting period, impacting overall profitability[130]. Acquisitions and Investments - The company completed the acquisition of the remaining 49% stake in Haikou Mary Hospital, enhancing its position in the healthcare sector[28]. - The company completed the acquisition of 100% equity in Haikou Mary Hospital Co., Ltd. on February 4, 2021, following board and shareholder approvals[50]. - The company signed an equity acquisition intention agreement with Beijing Guowei Dahui Medical Industry Fund on June 18, 2020, intending to purchase at least 20% equity in Guowei Reproductive Hospital[84]. - The non-public offering of 19,863,488 shares was approved by the China Securities Regulatory Commission on September 10, 2020, and the shares were listed for trading on June 4, 2021[91]. Market and Industry Focus - The company is focusing on expanding its market presence and enhancing its product offerings in the healthcare technology sector[19]. - The medical software industry is supported by national policies, with increasing emphasis on public health services due to the aging population and pandemic response[29]. - The assisted reproductive industry is expected to grow significantly due to declining birth rates and the implementation of the "three-child" policy[30]. - The company aims to leverage its brand and market position to expand through mergers and acquisitions in the highly regulated assisted reproductive market[31]. Research and Development - The company is actively pursuing new technology developments to enhance its service offerings in the medical field[19]. - The company has a mature R&D system certified by CMMI5, ensuring high standards in software development processes[39]. - The company emphasizes the importance of continuous R&D for new products and technology upgrades to maintain market competitiveness[63]. - Research and development expenses decreased by 33.79% to 14.31 million yuan, reflecting a shift in focus towards capitalizing on R&D costs[44]. Financial Health and Risks - The company has outlined potential risks in its report, which investors should be aware of[6]. - The company faces risks related to the large amount of accounts receivable, which could lead to increased bad debt provisions if major clients' financial conditions deteriorate[61]. - The ongoing pandemic has caused delays in project implementation and revenue recognition, significantly impacting the company's income[62]. - The company's revenue and net profit exhibit seasonal fluctuations, with contract signings and project payments concentrated in the second half of the year, particularly in Q4[62]. Transparency and Compliance - The company has not faced any issues with the authenticity and completeness of its financial disclosures[6]. - The company has a strong commitment to maintaining transparency and accuracy in its financial reporting[7]. - The company has established a profit distribution policy to protect the interests of minority investors, ensuring compliance with the relevant regulations[81]. Shareholder Information - The total number of ordinary shareholders as of the end of the reporting period is 35,519[94]. - The total number of shares held by the top ten shareholders is 56,568,000, accounting for 34.36% of the total shares[96]. - The company has committed to not exceeding 25% of its total shareholding for stock transfers during the tenure of its directors and senior management[78]. - The company ensures that any stock reduction after the lock-up period will not be below the initial public offering price[78]. Environmental Compliance - The company is not classified as a key pollutant discharge unit and actively complies with environmental protection policies[73]. - The company operates primarily in the software and information technology services industry, with no involvement in environmental pollution matters[74]. - The company has not taken measures to reduce carbon emissions during the reporting period[76]. Accounting and Financial Reporting - The financial statements are prepared in accordance with the relevant accounting standards, reflecting the company's financial position and operating results accurately[153]. - The company follows specific accounting policies for revenue recognition and asset depreciation based on its operational characteristics[152]. - The company’s accounting records are maintained in Renminbi (RMB)[156]. - The company has established a comprehensive framework for accounting treatment of business combinations, ensuring compliance with accounting standards[157].

Financial Performance - In 2020, the company's operating revenue was CNY 308,078,554.18, a decrease of 7.52% compared to CNY 333,116,193.35 in 2019[23]. - The net profit attributable to shareholders decreased by 24.41% to CNY 35,442,722.71 from CNY 46,887,055.64 in 2019[23]. - The net profit after deducting non-recurring gains and losses fell by 33.80% to CNY 25,812,050.75 compared to CNY 38,990,774.63 in 2019[23]. - The net cash flow from operating activities increased by 355.88% to CNY 100,479,244.99 from CNY 22,040,765.54 in 2019[23]. - The company's total assets increased by 100.15% to CNY 1,521,658,330.85 from CNY 760,265,101.93 in 2019[24]. - The net assets attributable to shareholders rose by 145.91% to CNY 1,226,498,334.77 from CNY 498,765,110.77 in 2019[24]. - Basic earnings per share decreased by 25.00% to CNY 0.24 from CNY 0.32 in 2019[25]. - The weighted average return on equity decreased by 4.02 percentage points to 5.66% from 9.68% in 2019[25]. - The company attributed the decline in net profit to a revenue drop of CNY 25,037,600 due to the pandemic, while fixed costs remained[26]. - The company reported a significant increase in revenue from the Mary Hospital, achieving 3,843.08 million RMB in operating income and a net profit of 1,341.43 million RMB for the year 2020[36]. Cash Dividend and Share Capital - The company plans to distribute a cash dividend of 0.66 CNY per 10 shares, totaling 10,766,328.41 CNY, which represents 30.38% of the net profit attributable to the parent company for 2020[5]. - The total share capital as of December 31, 2020, is 165,463,488 shares, after deducting 2,337,300 shares held in the repurchase account, the base for dividend distribution is 163,126,188 shares[5]. - In 2020, the net profit attributable to ordinary shareholders for 2020 was 35,443,025.23 CNY, with a profit distribution rate of 30.38%[119]. - In 2019, the cash dividend was 1.27 CNY per 10 shares, with a total of 14,281,756.55 CNY distributed, and a profit distribution rate of 30.46%[119]. - In 2018, the cash dividend was 2.10 CNY per 10 shares, totaling 16,933,314.30 CNY, with a profit distribution rate of 30.52%[121]. Audit and Compliance - The company has received a standard unqualified audit report from Zhonghui Certified Public Accountants[4]. - The board of directors and supervisory board confirm the authenticity, accuracy, and completeness of the annual report[7]. - The company has not violated decision-making procedures for external guarantees[7]. - There are no non-operating fund occupations by controlling shareholders or related parties[7]. - The company has established a plan to notify and disclose any share reduction intentions by major shareholders in advance[123]. - The company has a commitment to long-term shareholding, limiting annual share reductions to 25% of their total holdings[123]. Risks and Challenges - The company has detailed the main risks related to its operations in the report, including future development risks and countermeasures[8]. - The company emphasizes that forward-looking statements in the report involve uncertainties and do not constitute substantive commitments to investors[6]. - The company faces risks related to seasonal fluctuations in business operations, with revenue and net profit concentrated in the second half of the year, particularly in Q4[111]. - The company emphasizes the importance of continuous R&D for new products and technology upgrades to maintain market competitiveness, given the rapid evolution of software products[112]. Research and Development - The company’s total number of R&D personnel is 225, which constitutes 37.31% of the company's total workforce[73]. - Research and development expenses amounted to 43,032,347.82 CNY, representing 15.96% of total revenue[73]. - The company obtained 5 patents during the reporting period, including 3 invention patents and 2 utility model patents, enhancing its intellectual property portfolio[77]. - The company is focused on developing innovative solutions to improve the quality of care and patient outcomes in critical care settings[76]. Market Position and Strategy - The company has established a leading market position with its DoCare series clinical management information systems, which are applied in over 1,900 medical institutions across 32 provinces[46]. - The company aims to enhance its CIS business by developing three key areas: operating rooms, ICUs, and emergency rescue services, focusing on mobile, cloud, intelligent, and platform-based solutions[106]. - The company plans to actively seek acquisitions of qualified tertiary specialized hospitals or partnerships with qualified medical institutions to capture market share in the assisted reproductive medicine sector[99]. - The company is committed to improving medical quality management standards in its reproductive medicine services to mitigate clinical risks[113]. Financial Management - The company reported a significant increase in contract liabilities to ¥52,071,516.50, reflecting uncompleted contract work[87]. - The company’s cash dividend distribution plan proposes a payout of 0.66 yuan per 10 shares, totaling approximately 10.77 million yuan, which represents 30.38% of the net profit attributable to the parent company for 2020[118]. - The company is actively monitoring the performance of its financial products and adjusting strategies based on market conditions[149]. - The company has a financial management product linked to the London Interbank Offered Rate (LIBOR), with a potential yield of 1.40% per year if LIBOR exceeds 5%[151]. Subsidiaries and Acquisitions - The company completed the acquisition of 100% equity in Haikou Mary Hospital, with the relevant business license issued on March 23, 2021[140]. - The controlling subsidiary Haikou Mary Hospital Co., Ltd. has total assets of 37.63 million RMB and a net profit of 13.41 million RMB[97]. - The company signed a share acquisition intention agreement with the controlling shareholder of Beijing Guowei Health Reproductive Health Hospital, with due diligence completed[138]. Environmental Responsibility - The company actively fulfills its environmental responsibilities and complies with environmental policies, as it is not classified as a key pollutant discharge unit[157]. - The company has not disclosed environmental information for non-key pollutant discharge units due to the nature of its business, which primarily involves software development and does not contribute to environmental pollution[158].

Financial Performance - Operating revenue increased by 187.40% to CNY 47,093,244.80 compared to the same period last year[5] - Net profit attributable to shareholders was CNY 4,890,918.03, a significant recovery from a loss of CNY 17,397,120.67 in the previous year[5] - The company reported a basic earnings per share of CNY 0.04, recovering from a loss of CNY 0.11 per share in the previous year[7] - Revenue increased by CNY 30.71 million, a growth of 187.4%, mainly due to the recovery of operations to pre-pandemic levels and the consolidation of Haikou Mary Hospital's income[14] - Net profit for Q1 2021 was ¥7,929,049.10, compared to a net loss of ¥16,477,975.40 in Q1 2020, marking a turnaround in profitability[26] - The company's revenue for Q1 2021 reached ¥34,489,405.13, a significant increase of 196.5% compared to ¥11,608,748.61 in Q1 2020[28] Cash Flow - Cash flow from operating activities improved to a net outflow of CNY 13,196,761.79, compared to a larger outflow of CNY 19,172,443.55 in the same period last year[5] - Net cash flow from operating activities increased by CNY 5.98 million, driven by an increase of CNY 33.72 million in cash received from sales of goods and services compared to the same period last year[14] - Operating cash flow for Q1 2021 was negative at -¥13,196,761.79, an improvement from -¥19,172,443.55 in Q1 2020[31] - The cash inflow from operating activities was CNY 77,397,935.06, a 51.7% increase from CNY 51,005,829.75 in Q1 2020[34] - The net cash flow from operating activities was -CNY 1,797,672.97, an improvement from -CNY 6,856,776.43 in the same period last year[34] Assets and Liabilities - Total assets decreased by 10.55% to CNY 1,361,155,806.74 compared to the end of the previous year[5] - The company's total assets as of March 31, 2021, were ¥1,486,403,255.93, a decrease of 2.9% from ¥1,531,066,571.79 at the end of 2020[23] - Current assets totaled ¥1,062,725,146.95, down 13.1% from ¥1,222,338,242.75 at the end of 2020[23] - The total liabilities increased to ¥317,964,061.54, up from ¥303,058,756.33, reflecting a rise of 4.0%[23] - The company's equity decreased to ¥1,168,439,194.39 from ¥1,228,007,815.46, a decline of 4.9%[24] Investments and Acquisitions - The company acquired a 49% stake in Haikou Mary Hospital, impacting minority interests which decreased by 93.94%[13] - Investment activities generated a net cash outflow of CNY 433.09 million, mainly due to increased purchases of financial products and the acquisition of 49% equity in Haikou Mary Hospital[15] - The total investment cash outflow for Q1 2021 was ¥434,920,123.60, significantly higher than ¥46,862,939.59 in Q1 2020, reflecting aggressive investment strategies[32] Operating Costs and Expenses - Operating costs increased by CNY 6.35 million, a growth of 116.4%, primarily due to the increase in operating revenue[14] - Operating costs for Q1 2021 were ¥47,941,049.55, up from ¥39,960,895.44 in the same period last year, reflecting a year-over-year increase of 19.6%[24] - The company reported a total operating expenses of ¥30,294,431.28 in Q1 2021, up from ¥20,121,721.71 in Q1 2020, reflecting increased sales and management costs[28] Research and Development - Development expenses rose by 87.18% to CNY 1,146,780.00, mainly due to capitalized R&D costs for a new project[13] - Research and development expenses decreased by CNY 4.75 million, a reduction of 44.27%, due to the capitalization of R&D expenses related to a specific project[14] - Research and development expenses for Q1 2021 were ¥5,984,203.57, down 44.5% from ¥10,738,588.35 in Q1 2020[24] - Research and development expenses decreased to ¥1,730,670.40 in Q1 2021 from ¥8,189,283.64 in Q1 2020, indicating a strategic shift in resource allocation[28] Shareholder Information - The number of shareholders reached 12,006, indicating a stable shareholder base[9]

Financial Performance - In 2020, the company's operating revenue was CNY 308,078,554.18, a decrease of 7.52% compared to 2019[23]. - The net profit attributable to shareholders was CNY 35,442,722.71, down 24.41% from the previous year[23]. - The net cash flow from operating activities increased by 355.88% to CNY 100,479,244.99, primarily due to improved collection efforts[26]. - The total assets at the end of 2020 reached CNY 1,521,658,330.85, an increase of 100.15% compared to 2019[24]. - The net assets attributable to shareholders increased by 145.91% to CNY 1,226,498,334.77, mainly due to a private placement of shares[24]. - Basic earnings per share decreased by 25.00% to CNY 0.24 in 2020[25]. - The company reported a net loss of CNY 16,427,035.13 in Q1 2020, but recovered to a net profit of CNY 33,675,063.16 in Q4 2020[29]. - The company reported a net profit of 13.19 million in 2020, a decrease from 16.04 million in 2019, reflecting a decline of approximately 17.5%[32]. Dividend Distribution - The company plans to distribute a cash dividend of 0.66 CNY per 10 shares, totaling 10,766,328.41 CNY, which represents 30.38% of the net profit attributable to the parent company for 2020[5]. - As of December 31, 2020, the total share capital was 165,463,488 shares, with 2,337,300 shares held in the repurchase account, resulting in a base of 163,126,188 shares for the dividend distribution[5]. - The company’s cash dividend policy stipulates that at least 20% of the distributable profit should be distributed as cash dividends if certain conditions are met[119]. - The company’s cash dividends for the past three years have been consistent, with 2019 dividends at 1.27 RMB per 10 shares and 2018 at 2.10 RMB per 10 shares[121]. Audit and Compliance - The company has received a standard unqualified audit report from Zhonghui Certified Public Accountants[4]. - The board of directors and supervisory board confirm the authenticity, accuracy, and completeness of the annual report[7]. - The company has not violated decision-making procedures for external guarantees[7]. - There are no non-operating fund occupations by controlling shareholders or related parties reported[7]. - The company has not disclosed any significant changes in share capital or shareholder structure during the reporting period[10]. - The company has no major litigation or arbitration matters reported for the year[135]. - The company has not experienced any incidents of technology leakage or infringement during the reporting period, but acknowledges the potential risks associated with core technology[118]. Market and Operational Strategy - The company plans to continue focusing on R&D and market expansion to enhance its product offerings and competitive position[30]. - The company has a clear market expansion strategy in the reproductive medicine sector, having entered this field through the acquisition of Mary Hospital in 2019[36]. - The company aims to enhance its CIS business by developing three major segments: "Operating Room," "ICU," and "Emergency Rescue," focusing on increasing market penetration in the ICU segment[108]. - The company plans to expand its IVF business by integrating online and offline resources and pursuing external acquisitions to build a new reproductive health ecosystem[108]. - The company is strategically positioning itself for future growth by expanding its software capabilities and enhancing its product offerings in the healthcare sector[81]. Research and Development - R&D expenses amounted to 49,178,019.30, representing 15.96% of operating revenue[75]. - The company completed R&D on the DoCare intelligent management system for operating rooms, with an investment of 611.34 million[77]. - The DoCare critical care clinical information system 7.0 project received 789.97 million in funding and is aimed at enhancing clinical research and teaching capabilities[77]. - The company filed for and obtained 5 new patents during the reporting period, including 3 invention patents and 2 utility model patents[58]. - The company is focused on expanding its product offerings in pediatric critical care, with software developed for monitoring and decision support systems[81]. Financial Position and Shareholder Structure - The asset-liability ratio at the end of 2020 was 17.95%, a decrease of 15.34 percentage points from the beginning of the year[177]. - The total number of ordinary shareholders increased from 6,121 to 7,840 during the reporting period[179]. - The largest shareholder, Weng Kang, holds 21,872,760 shares, representing 13.22% of the total shares, with 10,338,883 shares pledged[181]. - The company has a high percentage of pledged shares, with 99.86% of the shares held by Weng Kang and Yan Huanghong being pledged, indicating potential risks related to stock price fluctuations[192]. - The company has committed to reducing and standardizing related party transactions with Mediston[128]. Risk Factors - The company has outlined potential risks in its operations and future development in the report[8]. - The report includes a forward-looking statement risk disclaimer, indicating uncertainties in future plans[6]. - The company faces risks related to the COVID-19 pandemic, which has delayed project implementations and affected revenue generation[111]. - Seasonal fluctuations in business operations may lead to lower net profits in the first two quarters of the year, making it essential for investors to consider annual performance rather than quarterly results[113]. Corporate Governance - The company has established a profit distribution decision-making process in accordance with its articles of association[128]. - The company appointed Hu Shaoan as the new vice general manager and board secretary on August 7, 2020, following the resignation of Fang Xianli[200]. - The company experienced a significant turnover in its board, with multiple resignations due to personal reasons, including directors Wang Jianhua and Kong Feng[199]. - The company’s management changes were part of a broader strategy to enhance governance and operational efficiency[200].

2020 年第三季度报告 公司代码：603990 公司简称：麦迪科技 苏州麦迪斯顿医疗科技股份有限公司 2020 年第三季度报告 1 / 27 | 目录 | | --- | | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司基本情况 | 3 | | 三、 | 重要事项 | 7 | | 四、 | 附录 | 9 | 2020 年第三季度报告 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人翁康、主管会计工作负责人万全军及会计机构负责人（会计主管人员）刘凤英保 证季度报告中财务报表的真实、准确、完整。 1.4 本公司第三季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 3 / 27 单位：元 币种：人民币 本报告期末 上年度末 本报告期末比上年度末增 减(%) 总资产 739,171,884.67 760,265,101.93 -2.77 归属于上市公司股东 的净资产 4 ...

Financial Performance - The company's operating revenue for the first half of the year was ¥89,072,084.25, a decrease of 25.97% compared to ¥120,321,519.90 in the same period last year[21]. - The net profit attributable to shareholders was a loss of ¥7,708,706.95, compared to a profit of ¥6,159,746.58 in the previous year, indicating a significant decline[22]. - The net cash flow from operating activities improved to ¥3,780,177.98, a reduction in outflow of ¥32,112,600 compared to the previous year[23]. - The company's total assets decreased by 0.56% to ¥755,998,740.63 from ¥760,265,101.93 at the end of the previous year[21]. - The basic earnings per share were -¥0.07, down 216.67% from ¥0.06 in the same period last year[22]. - The weighted average return on equity was -1.56%, a decrease of 2.86 percentage points compared to 1.30% last year[22]. - The company achieved operating revenue of 89.07 million yuan, a decrease of 25.97% compared to the same period last year, primarily due to a significant decline in revenue recognition scale[51]. - The net profit attributable to the parent company's shareholders was -7.71 million yuan, with a net profit of -9.53 million yuan after deducting non-recurring gains and losses, both showing a decline compared to the same period last year[51]. - The company reported a net loss from investments of CNY 41,389.40, an improvement compared to a loss of CNY 939,659.23 in the previous year[131]. - The total comprehensive income for the first half of 2020 was CNY -5,557,654.16, compared to CNY 5,750,908.50 in the first half of 2019[133]. Company Operations - The company has established a presence in 1,700+ medical institutions across 32 provinces, including over 500 top-tier hospitals[31]. - The company entered the assisted reproductive medical services sector through the acquisition of Mary Hospital, which has been operational since 2015[32]. - The company plans to invest in Beijing Guowei Reproductive Health Specialty Hospital to enhance research and talent in the assisted reproductive services field[32]. - The company focuses on digital hospital solutions and aims to integrate clinical applications with existing hospital information systems[30]. - The company has developed the DoCare series clinical medical management information system and Dorico digital operating room, which are now applied in over 1,700 medical institutions across 32 provinces in China, establishing a leading market position in clinical informationization[42]. - The company has established a marketing network covering 32 provinces, with service centers in major cities to enhance customer service and support[47]. - The company has developed a broad-spectrum medical device collection platform and medical information integration platform, laying a technical foundation for future product expansion[46]. - The company is actively participating in the application of 5G technology in its products, collaborating with Jiangsu Mobile to build a smart medical platform[50]. - The company has a mature product system and leading R&D technology, creating significant competitive advantages in the medical informationization field[48]. - The company focuses on technology innovation and the application of new technologies, particularly in the areas of operating rooms and emergency care products[50]. Market Trends - The assisted reproductive services market in China is expected to grow at a compound annual growth rate (CAGR) of 14.5%, reaching 49.6 billion yuan by 2023, driven by increasing infertility rates and the two-child policy[41]. - The infertility rate in China has risen from 2.5%-3% two decades ago to approximately 12.5%-15% currently, with projections indicating it may reach 18% in the near future[41]. - The software industry is supported by national policies, with a strategic focus on enhancing public health service capabilities, especially in the context of the COVID-19 pandemic[38]. Financial Position - The company's cash and cash equivalents increased by 68.37% to RMB 155.29 million, representing 20.54% of total assets[57]. - Short-term borrowings increased by 47.55% to RMB 152.79 million, indicating a rise in short-term financing needs[58]. - The company has total assets of 54.35 million RMB and a net profit of -2.26 million RMB for its wholly-owned subsidiary, Mediston (Beijing) Medical Technology Co., Ltd.[61]. - The total assets of the wholly-owned subsidiary, Shanghai Mediston Medical Technology Co., Ltd., are 1.48 million RMB, with a net profit of -2.42 million RMB[63]. - The total assets of the wholly-owned subsidiary, Suzhou Mediston Investment Management Co., Ltd., are 0.0197 million RMB, with a net profit of -0.03 million RMB[64]. - The total assets of the controlling subsidiary, Jilin Mediston Medical Technology Co., Ltd., are 3.93 million RMB, with a net profit of 0.1371 million RMB[66]. - The company has accounts receivable of 31.72 million RMB as of June 2020, which poses a risk due to long payment cycles from public hospital clients[69]. - The company reported a total current assets of RMB 473,330,254.43 as of June 30, 2020, compared to RMB 470,713,984.60 as of December 31, 2019, reflecting a slight increase[123]. - Cash and cash equivalents increased to RMB 155,286,220.44 from RMB 149,859,873.84, showing a growth of approximately 3.0%[123]. - Total assets amounted to RMB 755,998,740.63 as of June 30, 2020, down from RMB 760,265,101.93 at the end of 2019[124]. Risks and Challenges - The company has detailed risk factors described in the report, particularly in the section discussing operational conditions[6]. - The company faces risks from the recurring COVID-19 pandemic, which has delayed projects and affected revenue[70]. - The company acknowledges the potential for unpredictable internal and external factors to impact future operating performance stability[75]. - The company faces risks related to the rapid pace of software technology updates and the need for continuous product development to meet market demands[73]. - The company's revenue and net profit exhibit significant seasonal fluctuations, with lower profits in the first two quarters, potentially leading to losses[72]. Governance and Compliance - The company has held four shareholder meetings during the reporting period, ensuring compliance with legal and regulatory requirements[79]. - The company has committed to follow the profit distribution policy as outlined in its articles of association, including cash dividend policies[85]. - The company has implemented a stock option and restricted stock incentive plan, approved in March 2017, to motivate employees[86]. - The company did not distribute profits or increase capital reserves during the reporting period[4]. - There were no significant lawsuits or arbitration matters during the reporting period[86]. Accounting and Financial Reporting - The financial report has not been audited[7]. - The company's accounting policies comply with the relevant enterprise accounting standards, ensuring accurate financial reporting[167]. - The company's financial statements are prepared based on actual transactions and events, adhering to the accounting principles set forth by the Ministry of Finance[164]. - The company recognizes financial assets derecognition when the rights to cash flows have expired or when the risks and rewards of ownership have been transferred[193].

2020 年第一季度报告 二、 公司基本情况 2.1 主要财务数据 3 / 19 本报告期末 上年度末 本报告期末比上年度末增 减(%) 总资产 727,382,773.72 760,265,101.93 -4.33 归属于上市公司股东 的净资产 482,327,366.21 498,765,110.77 -3.30 年初至报告期末 上年初至上年报告期末 比上年同期增减(%) 经营活动产生的现金 流量净额 -19,172,443.55 -47,154,974.19 不适用 年初至报告期末 上年初至上年报告期末 比上年同期增减（%） 营业收入 16,385,763.42 40,950,266.98 -59.99 归属于上市公司股东 的净利润 -16,427,035.13 -4,099,719.71 不适用 归属于上市公司股东 的扣除非经常性损益 的净利润 -17,397,120.67 -4,705,884.30 不适用 加权平均净资产收益 率（%） -3.36 -0.87 不适用 基本每股收益（元/股） -0.15 -0.04 不适用 稀释每股收益（元/股） -0.15 -0.04 不适用 单位：元 币种：人民 ...

Financial Performance - The company's operating revenue for 2019 was CNY 333.12 million, an increase of 17.18% compared to CNY 284.28 million in 2018[22]. - The net profit attributable to shareholders for 2019 was CNY 46.89 million, a decrease of 15.49% from CNY 55.48 million in 2018[22]. - The net cash flow from operating activities decreased by 54.71% to CNY 22.04 million in 2019, down from CNY 48.67 million in 2018[24]. - The company's total assets increased by 6.00% to CNY 760.27 million at the end of 2019, compared to CNY 717.21 million at the end of 2018[22]. - The basic earnings per share for 2019 was CNY 0.42, a decline of 14.29% from CNY 0.49 in 2018[23]. - The company's gross profit for 2019 was CNY 239.76 million, reflecting a 13.31% increase from CNY 211.60 million in 2018[26]. - The total profit for the year was 53.92 million yuan, a decrease of 10.78% year-on-year[68]. - The company's net profit margin was 30.46% for 2019, with cash dividends representing a significant return to shareholders[157]. Dividend and Capital Distribution - The company plans to distribute a cash dividend of 1.27 CNY per 10 shares, totaling 14,281,756.55 CNY (including tax) to all shareholders[5]. - The total share capital for the dividend distribution plan is based on 112,454,776 shares[5]. - The company will increase its capital reserve by issuing 3 new shares for every 10 shares held, resulting in a total of 33,736,433 new shares[5]. - The company has a cash dividend policy that mandates a minimum of 20% of distributable profits to be paid out as cash dividends when conditions are met[154]. Acquisitions and Market Expansion - The company successfully acquired Mary Hospital, entering the assisted reproductive medical services sector, which contributed to the establishment of a dual development strategy in medical IT and reproductive services[38]. - The company aims to expand its IVF business and achieve a dual-driven development model by enhancing its CIS business and focusing on three key areas: operating rooms, ICUs, and emergency rescue[142]. - The company plans to actively seek acquisitions of qualified tertiary specialized hospitals or partnerships with qualified medical institutions to capture market share[134]. - The company has established a nationwide marketing network covering all 32 provinces, enhancing customer service and responsiveness[64]. Risks and Challenges - The company emphasizes that forward-looking statements in the report involve uncertainties and do not constitute a commitment to investors[6]. - The company has detailed the major risks associated with its operations in the report, including potential future challenges and countermeasures[7]. - The company faces risks related to seasonal fluctuations in business operations, with revenue and net profit concentrated in the second half of the year, particularly in Q4[148]. Research and Development - R&D expenses totaled CNY 57.69 million in 2019, accounting for 17.32% of total revenue, with 218 R&D personnel making up 36.58% of the total workforce[92]. - The company completed the development of the DoCare operating room management system, with an investment of ¥3.98 million[95]. - The mWiiCare clinical information system 2.0 project received an investment of ¥4.35 million, aimed at improving clinical workflow and data quality[97]. - The company is focusing on integrating high compatibility and high interconnectivity in its information systems to meet new medical standards[97]. Financial Audit and Compliance - The company has received a standard unqualified audit report from Zhonghui Certified Public Accountants[4]. - The company has committed to ensuring the accuracy and completeness of the financial report[5]. - The company appointed Zhonghui Certified Public Accountants (Special General Partnership) as the auditor for the 2019 fiscal year, with an audit fee of RMB 550,000[167]. Government Support and Market Trends - The total government subsidies recognized in the current period amounted to 13,193,074.87 RMB, up from 6,614,163.04 RMB in 2017, indicating increased support from governmental policies[33]. - The medical information technology market in China reached approximately 60 billion RMB in 2019, with a projected growth to over 110 billion RMB by 2024, indicating a sustained growth trend[50]. - The government has increased policy support for healthcare informationization, indicating an irreversible trend towards accelerated medical informationization[140]. Stock Options and Incentives - The company has implemented an employee stock option and restricted stock incentive plan, which was approved in March 2017[170]. - The company completed the repurchase and cancellation of 287,620 shares of restricted stock during the reporting period[171]. - The total number of stock options canceled was 287,770, with a repurchase price of 30.25 yuan per share[171]. - The company’s stock options and restricted stock incentive plan was approved on February 28, 2018[171]. Market Presence and Client Base - As of December 2019, the company had over 1,700 medical institution clients across 32 provinces in China, including more than 500 tertiary hospitals, indicating a strong market presence[39]. - The company's products are implemented in over 1,700 medical institutions across 32 provinces, establishing a strong market presence[61]. - The company has over 500 representative clients in top-tier hospitals, including major institutions like Peking University International Hospital and Shanghai Ruijin Hospital[61].

Financial Performance - Operating revenue for the first nine months was CNY 178,037,281.32, representing a 10.95% increase year-on-year[6] - Net profit attributable to shareholders decreased by 4.92% to CNY 10,863,587.59[6] - The total operating profit for the first three quarters of 2019 was ¥11,774,967.21, slightly down from ¥12,043,404.23 in the same period of 2018[31] - The net profit for Q3 2019 was CNY 1,274,632.57, a decrease from CNY 2,110,119.58 in Q3 2018, representing a decline of approximately 39.5%[35] - The total profit for Q3 2019 was ¥4,529,345.37, compared to ¥2,781,264.69 in Q3 2018, marking an increase of 63.0%[31] Assets and Liabilities - Total assets at the end of the reporting period were CNY 719,006,088.54, a 0.25% increase compared to the end of the previous year[6] - Total liabilities increased to CNY 295,506,625.50 from CNY 281,992,584.44 year-over-year[27] - Current liabilities totaled CNY 294,228,659.46, up from CNY 279,668,433.03 in the previous year[27] - Non-current liabilities decreased to CNY 1,277,966.04 from CNY 2,324,151.41 year-over-year[27] - Cash and cash equivalents decreased by 53.02 million yuan, a reduction of 31.45%, primarily due to increased payments for purchased goods and services, operational expenses, taxes, and investment intention funds[13] Shareholder Information - The total number of shareholders at the end of the reporting period was 5,449[11] - The largest shareholder, Weng Kang, held 14.90% of the shares, with 16,825,200 shares pledged[11] Cash Flow - Net cash flow from operating activities improved significantly, showing a net inflow of CNY -33,858,316.75, a 3,961.27% increase compared to the same period last year[6] - The net cash flow from operating activities decreased by 33.02 million yuan, a reduction of 3,961.27%, primarily due to increased cash payments for goods and services, employee compensation, and taxes[16] - The total cash inflow from operating activities was 213,857,605.61 RMB for the first nine months of 2019, slightly down from 218,994,147.59 RMB in the same period of 2018[41] - The cash flow from financing activities for the first nine months of 2019 was 9,388,964.61 RMB, compared to 14,166,924.63 RMB in the same period of 2018[42] Investments and Acquisitions - The company signed an agreement to acquire 51% of Haikou Mary Hospital Co., Ltd., a specialized hospital with qualifications for assisted reproductive technology, enhancing its market presence in the medical industry[18] - Other equity instrument investments increased by 3 million yuan, a 100% increase, primarily due to investments in Suzhou Aiyisitan Intelligent Technology Co., Ltd.[14] Operating Costs and Expenses - The total operating costs for Q3 2019 were ¥64,863,790.75, compared to ¥62,632,857.60 in Q3 2018, indicating an increase of 3.6%[30] - Research and development expenses increased to ¥15,858,140.96 in Q3 2019, up from ¥12,692,948.48 in Q3 2018, reflecting a growth of 25.5%[30] - The total operating expenses for Q3 2019 amounted to CNY 17,377,267.41, compared to CNY 20,666,739.93 in Q3 2018, indicating a reduction of about 16.5%[35]